Education
About Us
Working with TipRanks
Follow Us
Lyra Therapeutics, Inc. (LYRA)
:LYRA
LYRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.81 - $37.50
Previous CloseN/A
Volume832.93K
Average Volume (3M)79.41K
Market Cap
$10.52M
Enterprise Value$9.93M
Total Cash (Recent Filing)$31.73M
Total Debt (Recent Filing)$33.36M
Price to Earnings (P/E)―
Beta2.44
Next Earnings
Aug 12, 2025EPS Estimate
-5.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.50
Shares Outstanding1,598,376
10 Day Avg. Volume33,365
30 Day Avg. Volume79,410
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue8.38
Enterprise Value/Gross Profit-0.82
Enterprise Value/Ebitda-0.22
Forecast
1Y Price Target
$23.00Price Target Upside249.54% Upside
Rating ConsensusHold
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe ENLIGHTEN-2 trial achieved its primary endpoint with statistically significant improvement in the composite of the three cardinal symptoms of chronic rhinosinusitis for patients without nasal polyps.
Regulatory AlignmentLyra Therapeutics is aligned with the FDA on prospective pivotal Phase 3 development in non-polyp patients, pending the ENLIGHTEN-2 outcome and analysis.
Bears Say
Clinical Trial FailureThe ENLIGHTEN-1 trial failed to demonstrate statistically significant CRS benefit, contrasting with the success of the ENLIGHTEN-2 trial.
Stock Market ComplianceThe company announced plans to implement a reverse stock split to maintain compliance with NASDAQ listing standards.
Lyra Therapeutics News
LYRA FAQ
What was Lyra Therapeutics, Inc.’s price range in the past 12 months?
Lyra Therapeutics, Inc. lowest stock price was $3.81 and its highest was $37.50 in the past 12 months.
What is Lyra Therapeutics, Inc.’s market cap?
Lyra Therapeutics, Inc.’s market cap is $10.52M.
When is Lyra Therapeutics, Inc.’s upcoming earnings report date?
Lyra Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2025 which is in 7 days.
How were Lyra Therapeutics, Inc.’s earnings last quarter?
Lyra Therapeutics, Inc. released its earnings results on May 06, 2025. The company reported -$6.5 earnings per share for the quarter, beating the consensus estimate of -$7.5 by $1.
Is Lyra Therapeutics, Inc. overvalued?
According to Wall Street analysts Lyra Therapeutics, Inc.’s price is currently Undervalued.
Does Lyra Therapeutics, Inc. pay dividends?
Lyra Therapeutics, Inc. does not currently pay dividends.
What is Lyra Therapeutics, Inc.’s EPS estimate?
Lyra Therapeutics, Inc.’s EPS estimate is -5.53.
How many shares outstanding does Lyra Therapeutics, Inc. have?
Lyra Therapeutics, Inc. has 1,598,376 shares outstanding.
What happened to Lyra Therapeutics, Inc.’s price movement after its last earnings report?
Lyra Therapeutics, Inc. reported an EPS of -$6.5 in its last earnings report, beating expectations of -$7.5. Following the earnings report the stock price went up 2.941%.
Which hedge fund is a major shareholder of Lyra Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LYRA
Lyra Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$23.00 (249.54% Upside)
$23.00 (249.54% Upside)
Blogger Sentiment
Bullish
LYRA Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 112.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.03%
12-Months-Change
Fundamentals
Return on Equity
-195.46%
Trailing 12-Months
Asset Growth
-60.21%
Trailing 12-Months
Company Description
Lyra Therapeutics, Inc.
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
LYRA Stock 12 Month Forecast
Average Price Target
$23.00
▲(249.54%Upside)
Technical Analysis
Brainstorm Cell Therapeutics
―
GT Biopharma
―
Genprex
―
Spruce Biosciences
―
Conduit Pharmaceuticals
―
Ownership Overview
3.27% Insiders
3.85% Mutual Funds
24.14% Other Institutional Investors
61.86% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---